▁Sub 6.6640625
title 4.55078125
: 0.78271484375
▁Ag 8.515625
gress 3.82421875
ive 0.1444091796875
▁Mark 5.08203125
eting 0.0258636474609375
▁Cla 9.3125
ims 0.0438232421875
▁Must 6.2265625
▁be 1.4794921875
▁Sc 6.5703125
rut 0.027130126953125
in 0.0007314682006835938
ized 0.081298828125
▁to 4.4375
▁Ens 2.09375
ure 0.0004208087921142578
▁Effect 5.0234375
iveness 0.54638671875
▁and 2.01171875
▁Pat 6.640625
ient 0.056854248046875
▁Saf 0.20458984375
ety 0.0018434524536132812
<0x0A> 0.2763671875
By 3.626953125
▁[ 9.796875
Your 7.6796875
▁Name 0.1396484375
] 0.91748046875
<0x0A> 0.9443359375
[ 3.515625
date 6.609375
] 0.861328125
<0x0A> 1.486328125
In 3.98046875
▁an 3.552734375
▁industry 3.876953125
▁eager 6.91015625
ly 3.79296875
▁await 1.720703125
ing 0.005615234375
▁ground 7.77734375
bre 0.22802734375
aking 3.349781036376953e-05
▁adv 2.921875
anc 1.3857421875
ements 2.3126602172851562e-05
▁in 0.37109375
▁cancer 2.716796875
▁treatment 0.97998046875
, 0.1370849609375
▁a 3.427734375
▁British 8.0078125
▁bi 2.703125
ote 0.14697265625
ch 0.46337890625
▁company 0.331787109375
▁has 1.4013671875
▁recently 2.583984375
▁announced 1.802734375
▁positive 5.00390625
▁early 3.572265625
- 1.9296875
stage 0.1651611328125
▁results 0.73486328125
▁for 1.1318359375
▁their 2.83984375
▁experimental 2.8671875
▁cancer 1.5703125
▁drug 1.0283203125
, 1.232421875
▁generating 10.5390625
▁significant 2.52734375
▁excitement 2.119140625
▁among 1.9560546875
▁patients 2.6640625
, 1.224609375
▁health 3.10546875
care 0.485107421875
▁profession 0.775390625
als 1.0013580322265625e-05
, 0.380615234375
▁and 0.1343994140625
▁invest 0.57958984375
ors 0.004222869873046875
▁al 1.37109375
ike 9.5367431640625e-07
. 0.0545654296875
▁Non 8.1171875
eth 0.026824951171875
eless 0.00033473968505859375
, 0.002040863037109375
▁industry 5.984375
▁anal 2.20703125
yst 0.0017957687377929688
s 0.0032825469970703125
▁are 1.806640625
▁ur 2.701171875
ging 0.00647735595703125
▁c 4.5859375
aut 0.0018968582153320312
ious 0.0027618408203125
▁optim 0.0849609375
ism 0.0002803802490234375
, 0.9501953125
▁stress 3.83203125
ing 8.428096771240234e-05
▁the 0.64794921875
▁importance 1.0283203125
▁of 0.004077911376953125
▁rig 2.931640625
orous 0.099365234375
▁scr 2.482421875
ut 2.3484230041503906e-05
iny 0.008636474609375
▁to 2.115234375
▁ensure 0.390625
▁the 1.0166015625
▁drug 1.3935546875
' 0.6171875
s 8.547306060791016e-05
▁effect 0.8662109375
iveness 0.0008363723754882812
▁and 0.08197021484375
▁safety 0.9228515625
▁for 2.390625
▁patients 0.317138671875
. 0.1201171875
<0x0A> 0.1763916015625
The 1.0322265625
▁cancer 4.6953125
▁drug 0.22998046875
, 0.5458984375
▁developed 2.0
▁by 0.0210418701171875
▁the 2.322265625
▁British 1.0556640625
▁bi 0.315185546875
ote 0.043182373046875
ch 0.053436279296875
▁firm 2.0078125
, 2.001953125
▁has 2.42578125
▁shown 1.099609375
▁encourag 3.3359375
ing 9.059906005859375e-05
▁signs 2.474609375
▁of 0.327880859375
▁effic 1.078125
acy 2.3603439331054688e-05
▁in 0.1884765625
▁early 1.4443359375
▁clin 1.5205078125
ical 9.799003601074219e-05
▁tri 0.0244598388671875
als 5.602836608886719e-06
. 1.4111328125
▁Pre 5.328125
lim 0.11669921875
inary 6.532669067382812e-05
▁data 0.9384765625
▁indicates 2.02734375
▁that 0.0904541015625
▁it 2.65625
▁effectively 4.7890625
▁targets 2.091796875
▁cancer 2.224609375
▁cells 0.163818359375
, 1.4072265625
▁th 10.953125
wart 0.0350341796875
ing 0.00026035308837890625
▁their 0.385009765625
▁growth 0.78515625
▁and 0.0885009765625
▁pro 1.787109375
l 0.09033203125
ifer 5.412101745605469e-05
ation 8.678436279296875e-05
, 1.8017578125
▁and 1.501953125
▁exhib 5.8515625
its 0.05419921875
▁potential 5.01953125
▁as 1.3154296875
▁a 0.10540771484375
▁th 4.015625
era 0.00016176700592041016
pe 4.76837158203125e-06
ut 1.5497207641601562e-06
ic 0.0005464553833007812
▁break 6.234375
through 9.298324584960938e-05
▁in 1.2900390625
▁various 5.69921875
▁types 1.0810546875
▁of 0.0007219314575195312
▁cancer 0.2288818359375
, 1.5888671875
▁including 0.2017822265625
▁not 8.84375
or 0.5068359375
iously 3.921985626220703e-05
▁hard 2.765625
- 0.01262664794921875
to 0.00023627281188964844
- 0.00020742416381835938
tre 0.002964019775390625
at 1.9788742065429688e-05
▁m 3.298828125
align 0.0032787322998046875
an 0.020233154296875
cies 0.00012063980102539062
. 0.7578125
<0x0A> 0.55712890625
Th 4.73046875
ese 0.267822265625
▁g 8.8671875
lim 0.2958984375
ps 1.541015625
es 0.0009393692016601562
▁of 0.0645751953125
▁success 3.24609375
▁have 0.53759765625
▁spark 1.798828125
ed 0.0001024007797241211
▁optim 3.955078125
ism 0.0369873046875
▁for 2.990234375
▁the 0.8681640625
▁development 4.34765625
▁of 0.05975341796875
▁a 1.13671875
▁much 3.021484375
- 0.005916595458984375
ne 0.0261077880859375
eded 1.537799835205078e-05
▁alternative 3.009765625
▁for 3.12109375
▁patients 0.78662109375
▁whose 3.578125
▁treatment 3.326171875
▁options 0.02117919921875
▁have 1.88671875
▁been 0.5615234375
▁limited 0.41064453125
. 1.9228515625
▁However 1.396484375
, 0.00011515617370605469
▁anal 3.38671875
yst 0.0002968311309814453
s 0.0008521080017089844
▁are 1.1884765625
▁rem 3.8515625
inding 0.0032634735107421875
▁the 0.8310546875
▁medical 3.66015625
▁community 0.0660400390625
▁and 1.7333984375
▁invest 1.9248046875
ors 0.0254058837890625
▁that 1.3330078125
▁ca 3.443359375
ution 7.510185241699219e-05
▁must 1.974609375
▁always 5.09375
▁accomp 2.228515625
any 2.193450927734375e-05
▁enthus 1.8349609375
ias 0.031768798828125
m 0.0003788471221923828
▁in 1.50390625
▁the 0.63134765625
▁field 1.7021484375
▁of 0.0225372314453125
▁experimental 5.640625
▁dru 2.453125
gs 1.4185905456542969e-05
. 0.345947265625
<0x0A> 0.473876953125
" 3.00390625
Wh 1.5732421875
ile 0.00246429443359375
▁the 1.2109375
▁early 0.93505859375
▁results 1.2216796875
▁are 0.6455078125
▁certainly 2.43359375
▁prom 0.55322265625
ising 4.38690185546875e-05
, 0.06884765625
▁it 0.88623046875
' 0.55908203125
s 7.76052474975586e-05
▁essential 1.8974609375
▁to 0.34765625
▁recognize 3.27734375
▁that 0.11993408203125
▁further 4.609375
▁investigation 3.634765625
▁and 1.2705078125
▁more 5.16796875
▁extensive 1.00390625
▁clin 0.74951171875
ical 6.985664367675781e-05
▁tri 0.07000732421875
als 1.9550323486328125e-05
▁are 0.1533203125
▁needed 1.4716796875
▁to 0.270263671875
▁fully 1.9677734375
▁understand 1.583984375
▁the 0.05224609375
▁drug 0.226318359375
' 0.0036220550537109375
s 2.7894973754882812e-05
▁effect 1.8642578125
iveness 0.006000518798828125
, 3.287109375
▁side 3.82421875
▁effects 0.02056884765625
, 0.0180511474609375
▁and 0.0108184814453125
▁potential 1.0068359375
▁long 1.888671875
- 0.0005054473876953125
term 0.0004215240478515625
▁ris 2.876953125
ks 3.5762786865234375e-07
," 0.271240234375
▁says 2.388671875
▁Dr 0.97705078125
. 0.0027675628662109375
▁Jane 3.953125
▁Sim 6.140625
m 1.251953125
ons 0.008056640625
, 0.0643310546875
▁a 0.3115234375
▁ren 2.32421875
owned 0.00012302398681640625
▁on 0.23583984375
colog 0.0633544921875
ist 0.00164794921875
▁from 3.4765625
▁a 4.140625
▁pr 2.130859375
estig 1.895427703857422e-05
ious 3.743171691894531e-05
▁medical 1.166015625
▁inst 2.611328125
itute 7.617473602294922e-05
. 0.46044921875
<0x0A> 0.76318359375
Anal 4.51953125
yst 0.019439697265625
s 0.00791168212890625
▁cont 6.25390625
end 0.004947662353515625
▁that 0.006221771240234375
▁companies 6.01171875
▁in 4.09765625
▁the 0.169189453125
▁bi 1.388671875
ote 0.326416015625
ch 0.14697265625
▁space 3.158203125
▁often 2.947265625
▁face 5.484375
▁immense 3.7265625
▁pressure 0.1922607421875
▁– 9.796875
▁both 1.095703125
▁internal 1.5869140625
▁and 0.012481689453125
▁external 0.0242767333984375
▁– 0.022430419921875
▁to 0.01422882080078125
▁present 3.669921875
▁their 1.138671875
▁dru 1.7099609375
gs 1.9073486328125e-06
▁as 1.3505859375
▁ground 3.681640625
break 6.125
ers 0.0787353515625
, 1.255859375
▁creating 5.203125
▁an 1.4765625
▁atmosphere 2.10546875
▁of 1.4404296875
▁elev 8.109375
ated 0.0019102096557617188
▁expect 0.37060546875
ations 0.0005407333374023438
. 1.5625
▁Sub 6.4296875
sequently 0.1455078125
, 0.001079559326171875
▁invest 3.923828125
ors 0.034942626953125
▁may 1.515625
▁h 7.76171875
inge 3.708984375
▁their 0.1712646484375
▁hopes 5.94921875
▁on 0.328369140625
▁early 2.708984375
- 1.017578125
stage 0.033233642578125
▁data 1.5537109375
▁that 2.0625
▁is 2.0
▁yet 3.65625
▁to 0.0174102783203125
▁be 0.11602783203125
▁valid 2.2265625
ated 5.555152893066406e-05
▁by 1.4462890625
▁larger 1.990234375
, 1.4609375
▁more 0.403564453125
▁compreh 1.373046875
ensive 0.00037789344787597656
▁tri 1.2587890625
als 2.0265579223632812e-06
. 0.269287109375
▁Several 9.3359375
▁previous 4.57421875
▁instances 2.4765625
▁have 1.15234375
▁demonstrated 1.365234375
▁the 1.01171875
▁per 3.029296875
ils 0.145263671875
▁of 0.0592041015625
▁over 2.408203125
h 2.23046875
yp 0.047607421875
ing 0.326171875
▁dru 3.169921875
gs 1.5616416931152344e-05
▁prem 3.671875
ature 0.0001386404037475586
ly 0.00035119056701660156
, 0.40966796875
▁leading 1.8779296875
▁to 0.0302276611328125
▁dashed 3.7421875
▁hopes 1.279296875
, 2.06640625
▁was 2.455078125
ted 0.0013055801391601562
▁resources 0.7509765625
, 0.016357421875
▁and 0.007091522216796875
▁patient 3.443359375
▁disappoint 3.19140625
ment 0.033172607421875
. 0.07391357421875
<0x0A> 0.10357666015625
Dr 4.23828125
. 0.002826690673828125
▁David 4.6328125
▁Thompson 5.56640625
, 0.0406494140625
▁a 0.36669921875
▁regul 6.52734375
atory 0.00010776519775390625
▁expert 0.83740234375
, 1.5302734375
▁acknowled 4.51953125
ges 0.031402587890625
▁the 0.86376953125
▁need 2.32421875
▁for 0.28955078125
▁optim 3.43359375
ism 0.08831787109375
▁while 3.30859375
▁ca 2.220703125
ution 0.00016546249389648438
ing 0.0010166168212890625
▁against 0.3505859375
▁un 2.15625
checked 3.525390625
▁enthus 0.347900390625
ias 0.0003991127014160156
m 7.653236389160156e-05
. 0.314697265625
▁" 0.490966796875
It 1.73828125
' 0.1312255859375
s 8.96453857421875e-05
▁essential 1.97265625
▁for 2.259765625
▁the 1.9560546875
▁public 3.365234375
, 1.400390625
▁regul 3.255859375
ators 0.2890625
, 0.00595855712890625
▁and 0.08526611328125
▁health 2.365234375
care 0.026031494140625
▁profession 0.36376953125
als 3.337860107421875e-06
▁to 0.07928466796875
▁crit 4.41796875
ically 1.3113021850585938e-05
▁evaluate 0.6796875
▁the 0.728515625
▁claims 1.3369140625
▁made 0.59326171875
▁by 0.09112548828125
▁bi 1.322265625
ote 0.01708984375
ch 0.039337158203125
▁companies 0.166015625
▁and 1.3740234375
▁independently 8.59375
▁verify 1.240234375
▁the 0.775390625
▁data 1.5869140625
," 2.224609375
▁he 0.10589599609375
▁ca 6.54296875
utions 0.06890869140625
. 0.094970703125
▁" 1.25390625
Bal 9.8515625
ancing 0.5703125
▁hope 1.9580078125
▁with 0.423828125
▁scientific 2.98828125
ally 5.234375
▁sound 0.66650390625
▁evidence 0.97021484375
▁is 0.2088623046875
▁critical 2.94921875
▁for 1.833984375
▁avoid 6.2421875
ing 3.337860107421875e-05
▁unnecessary 3.0078125
▁set 2.6953125
back 4.8041343688964844e-05
s 0.0001277923583984375
▁down 4.63671875
▁the 0.00086212158203125
▁line 0.85546875
." 0.07537841796875
<0x0A> 0.01548004150390625
Reg 5.03125
ul 0.23095703125
atory 0.79150390625
▁authorities 1.2724609375
, 1.6240234375
▁such 0.6376953125
▁as 0.00012159347534179688
▁the 0.01141357421875
▁Food 1.279296875
▁and 0.01299285888671875
▁D 0.0009021759033203125
rug 2.6226043701171875e-06
▁Administration 0.0016832351684570312
▁( 0.1846923828125
F 0.0005655288696289062
DA 0.00014734268188476562
) 0.611328125
▁and 1.75390625
▁the 0.427490234375
▁European 0.08599853515625
▁Medic 0.025848388671875
ines 0.00020003318786621094
▁Agency 0.0023441314697265625
▁( 0.0667724609375
EMA 0.00016748905181884766
), 0.0256195068359375
▁play 2.130859375
▁a 0.13720703125
▁central 5.48046875
▁role 0.0008559226989746094
▁in 0.0022678375244140625
▁ens 0.9873046875
uring 1.1682510375976562e-05
▁the 0.962890625
▁integrity 4.1171875
▁and 0.95751953125
▁safety 0.8359375
▁of 0.0005068778991699219
▁new 2.29296875
▁drug 3.3828125
▁candidates 1.8037109375
. 0.147705078125
▁As 4.26171875
▁research 6.21484375
▁progress 2.33203125
es 0.003589630126953125
, 0.59033203125
▁it 3.94140625
▁is 0.60400390625
▁cru 1.5283203125
cial 8.547306060791016e-05
▁that 1.193359375
▁these 1.3193359375
▁ag 0.6328125
encies 7.939338684082031e-05
▁maintain 1.9921875
▁a 0.578125
▁watch 2.85546875
ful 0.000461578369140625
▁eye 0.0077056884765625
▁on 1.38671875
▁the 0.67822265625
▁development 1.798828125
▁process 1.119140625
, 0.55859375
▁guarantee 6.89453125
ing 0.0019292831420898438
▁that 0.28662109375
▁the 1.5849609375
▁drug 2.384765625
' 1.2958984375
s 4.8041343688964844e-05
▁effic 2.30078125
acy 2.7060508728027344e-05
▁and 0.408935546875
▁safety 0.07501220703125
▁profiles 5.76953125
▁align 3.2265625
▁with 0.005741119384765625
▁the 0.61865234375
▁highest 7.57421875
▁standards 0.467529296875
. 0.796875
<0x0A> 0.114990234375
More 4.50390625
over 0.2196044921875
, 0.00012087821960449219
▁open 8.0625
▁and 1.298828125
▁transparent 0.7412109375
▁communication 0.15380859375
▁between 0.79638671875
▁the 1.62109375
▁bi 1.1650390625
ote 0.0211944580078125
ch 0.01517486572265625
▁firm 1.810546875
▁and 0.44482421875
▁the 0.86865234375
▁wider 4.265625
▁scientific 2.349609375
▁community 0.0928955078125
▁is 0.2149658203125
▁essential 1.5712890625
. 1.615234375
▁Re 5.2890625
le 0.81201171875
asing 9.894371032714844e-05
▁compreh 3.740234375
ensive 0.0032444000244140625
▁data 1.0087890625
, 1.978515625
▁including 1.0224609375
▁the 2.560546875
▁drug 2.328125
' 0.0163726806640625
s 3.7550926208496094e-05
▁mechanism 2.19921875
▁of 0.00971221923828125
▁action 0.00036978721618652344
, 0.1763916015625
▁statistical 7.00390625
▁anal 2.111328125
ys 9.417533874511719e-06
es 0.00011169910430908203
, 0.0716552734375
▁and 0.055206298828125
▁potential 1.9970703125
▁side 0.837890625
▁effects 0.0050506591796875
, 0.046844482421875
▁fost 3.79296875
ers 0.0022754669189453125
▁an 2.376953125
▁environment 0.489013671875
▁of 0.05438232421875
▁trust 1.2294921875
, 2.27734375
▁en 2.45703125
abling 0.1370849609375
▁other 3.443359375
▁exper 1.546875
ts 9.5367431640625e-07
▁to 0.0968017578125
▁conduct 2.98046875
▁peer 5.80078125
▁reviews 0.5732421875
▁and 0.2325439453125
▁independent 4.89453125
▁anal 1.240234375
ys 4.00543212890625e-05
es 2.9802322387695312e-05
▁for 4.75390625
▁validation 3.830078125
. 0.1837158203125
<0x0A> 0.1683349609375
U 3.1015625
lt 0.01355743408203125
imately 4.863739013671875e-05
, 7.30752944946289e-05
▁the 0.94580078125
▁ar 9.8515625
du 0.85986328125
ous 0.00034427642822265625
▁journey 0.865234375
▁from 1.3056640625
▁prom 2.998046875
ising 0.00018072128295898438
▁early 1.1513671875
- 0.29150390625
stage 0.00537109375
▁results 0.982421875
▁to 0.00589752197265625
▁a 2.14453125
▁successfully 5.9921875
▁approved 0.78125
▁cancer 3.8359375
▁treatment 2.181640625
▁involves 3.31640625
▁multiple 3.017578125
▁stages 1.9404296875
▁of 0.31787109375
▁extensive 5.23046875
▁research 1.7900390625
, 0.603515625
▁scr 4.26953125
ut 0.00010573863983154297
iny 0.06805419921875
, 0.0223846435546875
▁and 0.03729248046875
▁collaboration 3.96875
. 0.266845703125
▁While 1.5283203125
▁the 0.83251953125
▁British 3.806640625
▁bi 0.02496337890625
ote 0.0007305145263671875
ch 0.0022716522216796875
▁company 1.1064453125
' 0.232421875
s 7.510185241699219e-05
▁cancer 3.216796875
▁drug 0.012237548828125
▁has 1.318359375
▁und 7.19921875
eni 1.83203125
ably 0.1468505859375
▁shown 1.33984375
▁initial 4.8046875
▁promise 0.8125
, 0.0533447265625
▁anal 3.2109375
yst 5.817413330078125e-05
s 0.00018107891082763672
▁and 1.9267578125
▁industry 2.09765625
▁exper 0.216064453125
ts 1.9073486328125e-06
▁ca 3.23828125
ution 0.00014126300811767578
▁against 0.3818359375
▁und 4.203125
ue 0.06475830078125
▁ex 3.1875
uber 0.016693115234375
ance 6.711483001708984e-05
, 0.779296875
▁stress 1.4560546875
ing 7.748603820800781e-05
▁the 0.07464599609375
▁need 1.162109375
▁for 0.0601806640625
▁thorough 3.439453125
▁scientific 3.212890625
▁evaluation 0.92919921875
▁before 4.05078125
▁making 1.9111328125
▁le 7.984375
aps 0.0150146484375
▁of 0.025146484375
▁faith 0.11627197265625
. 0.08746337890625
<0x0A> 0.490478515625
As 3.474609375
▁patients 4.85546875
, 1.0947265625
▁health 0.4248046875
care 0.004055023193359375
▁profession 0.08612060546875
als 1.1920928955078125e-06
, 0.001953125
▁and 0.108642578125
▁invest 0.049163818359375
ors 8.45193862915039e-05
▁eager 1.3984375
ly 0.0001214742660522461
▁anticip 1.5048828125
ate 0.0006699562072753906
▁further 3.552734375
▁develop 0.55517578125
ments 1.7642974853515625e-05
, 0.89208984375
▁it 0.55810546875
▁is 0.1705322265625
▁vital 2.634765625
▁to 0.2454833984375
▁recognize 2.56640625
▁the 0.97509765625
▁importance 1.1787109375
▁of 0.0013456344604492188
▁maintain 2.5703125
ing 0.0001119375228881836
▁a 0.27685546875
▁c 2.873046875
aut 0.00014841556549072266
ious 0.087646484375
▁and 1.1669921875
▁evidence 2.552734375
- 1.609325408935547e-05
based 0.08258056640625
▁approach 0.162353515625
. 1.154296875
▁Only 2.13671875
▁through 1.0576171875
▁robust 5.12890625
▁scientific 1.5068359375
▁validation 2.802734375
▁and 0.4990234375
▁objective 7.04296875
▁evaluation 1.54296875
▁can 0.1494140625
▁the 1.625
▁hopes 6.5625
▁raised 5.4921875
▁by 0.00829315185546875
▁such 3.6640625
▁ground 2.8125
bre 0.024261474609375
aking 0.0010433197021484375
▁research 3.486328125
▁be 0.29345703125
▁transformed 3.359375
▁into 0.0023670196533203125
▁genu 3.689453125
ine 0.06103515625
▁treatment 5.671875
▁options 1.4345703125
▁that 1.0478515625
▁extend 8.84375
▁and 2.0859375
▁improve 0.458740234375
▁the 0.77099609375
▁lives 0.1239013671875
▁of 0.0003323554992675781
▁cancer 1.1630859375
▁patients 0.019927978515625
▁world 0.7158203125
wide 3.3974647521972656e-05
. 0.006076812744140625
